Last reviewed · How we verify
NCT07225751: ASTRA
A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions
NA trial testing MagnetOs in Ankle Arthrodesis or Arthroplasty in 126 participants. Currently enrolling.
1 October 2028
Quick facts
| Lead sponsor | Kuros Biosurgery AG |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 126 |
| Start date | 25 November 2025 |
| Primary completion | 1 October 2028 |
| Estimated completion | 1 December 2028 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- MagnetOs
- Autograft
Conditions studied
- Ankle Arthrodesis or Arthroplasty — all drugs for Ankle Arthrodesis or Arthroplasty →
- Hindfoot Fusion — all drugs for Hindfoot Fusion →
- Ankle Deformity — all drugs for Ankle Deformity →
- Ankle Disease — all drugs for Ankle Disease →
Sponsor
Kuros Biosurgery AG — full company profile →
Who can join
Adults 18 to 75, any sex, with Ankle Arthrodesis or Arthroplasty or Hindfoot Fusion. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Radiographic fusion by CT scan
Time frame: Week 24 post-op
The primary endpoint is the incidence of fusion at each side by CT analysis as assessed by the independent radiological expert at 24 weeks post-op
Sponsor's own description
This is a phase IV post-marketing study for MagnetOs Putty and MagnetOs Easypack Putty. MagnetOs is a synthetic bone graft extender product that is routinely used by surgeon as treatment for hindfoot and ankle disorders. In this study, MagnetOs Putty and MagnetOs Easypack Putty will be use according to the latest Instructions For Use, standalone in the foot and ankle.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07225751
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Kuros Biosurgery AG trials
Trials by the same sponsor.
- NCT04679844 — Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Au · NA · recruiting
- NCT04679896 — Post Marketing Study of MagnetOs Putty Compared to Local Autograft in Patients Undergoing Posterolateral Lumbar Fusion · NA · completed
- NCT04294004 — KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07225751 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kuros Biosurgery AG
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07225751.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing